Latest news for MicroAlgo (OTC:VENAF) Stock

MicroAlgo Inc is divided into two segments Central processing algorithm services & Intelligent chips and services. The majority is from the Central processing algorithm services. which refer to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.

MicroAlgo Inc

JP Morgan analyst Samik Chatterjee maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and raises the price target from $245 to $265.

News

Price Target

Analyst Ratings

AAPL

JP Morgan Maintains Overweight on Apple, Raises Price Target to $265

– Collaboration combines Dren's targeted cell depletion platform with Novartis research, development and commercial expertise to advance innovative therapies for cancer –
– Dren Bio to receive total upfront consideration of $150 million and is eligible to receive milestone payments and tiered royalties –
Dren Bio, Inc. ("Dren Bio" or the "Company"), a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>). The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform.

Biotech

General

Dren Bio Announces Strategic Collaboration with Novartis To Develop Novel Targeted Myeloid Engagers For Cancer; Dren Bio To Receive Total Upfront Consideration Of $150M And Is Eligible To Receive Milestone Payments And Tiered Royalties

WIIM

NUWE

Nuwellis shares are trading lower after the company announced the pricing of a $2 million public offering of 469,340 common shares at $4.24 a share.

Tower Semiconductor Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) reported a fiscal second-quarter 2024 revenue decline of 1.7% year-on-year to $351.2 million, beating the <a href="https://www.benzinga.com/pressreleases/24/07/g39927653/tower-semiconductor-reports-2024-second-quarter-financial-results" target="_blank" rel="noreferrer noopener">analyst consensus estimate of $350.1 million</a>.
The Israel-based contract chipmaker's adjusted EPS of $0.53 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $0.45</a>.
Gross profit was $86.9 million, up 0.5% Y/Y.&nbsp;The margin improved by 53 bps to 24.8%. Operating profit of $55.1 million climbed 9%&nbsp;Y/Y.
The company generated $113 million in operating cash flow and held $1.23 billion in cash and equivalents&nbsp;as of June-end.
Outlook: Tower Semiconductor expects third-quarter revenue of $370 million, with an upward or downward range of 5% versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$369.9 million consensus</a>.
Tower Semiconductor has been asked by the Indian government to revise its chip fabrication unit proposal to include a technology partner offering advanced nodes for manufacturing, Economic Times <a target="_blank" href="https://economictimes.indiatimes.com/tech/technology/govt-asks-israels-tower-to-rework-chip-fab-proposal/articleshow/110341422.cms?from=mdr" rel="noreferrer noopener">reported</a> in May.
The government prefers Tower Semiconductor to focus on 28 nm, 40 nm, 55 nm, and 65 nm nodes instead of just the proposed 180 nm node plan.
Tower Semiconductor has submitted an $8-10 billion proposal for a unit in India, potentially making it one of their largest, but faces legal challenges following the fallout with joint venture partner Next Orbit Ventures.
Tower Semiconductor stock gained 18% in the last 12 months.
<h2 class="wp-block-heading">TSEM Stock Prediction 2024</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Tower Semiconductor have an average 1-year price target of $49.67, representing an expected upside of 20.31%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Tower Semiconductor, while 3 analysts have bullish ratings. The street high price target from Susquehanna is $55.0, while the street low from Craig-Hallum is $44.0.
TSEM Price Action: Tower Semiconductor shares traded lower by 2.46% at $40.27 premarket at the last check Wednesday. 
Photo via Shutterstock

Earnings

Equities

Guidance

Media

TSEM

Tower Semiconductor Shares Fall on Q2 Revenue Decline: Details

Stifel analyst Benjamin Nolan maintains Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) with a Buy and raises the price target from $84 to $86.

STNG

Stifel Maintains Buy on Scorpio Tankers, Raises Price Target to $86

Blue Foundry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFY#NASDAQ">BLFY</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 37.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $10.109 million which beat the analyst consensus estimate of $9.441 million by 7.08 percent. This is a 10.43 percent decrease over sales of $11.286 million the same period last year.

Earnings Beats

BLFY

Blue Foundry Q2 2024 GAAP EPS $(0.11) Beats $(0.21) Estimate, Sales $10.109M Beat $9.441M Estimate

Clearwater Paper To Sell Tissue Business To Sofidel America For $1.06B; Transaction To Reduce Net Debt And Advance Transformation Into Premier Independent Supplier Of Paperboard To North American Converters

RNAZ

TransCode Therapeutics Files For Offering Of Up To 10M Shares Of Common Stock

JP Morgan analyst Doug Anmuth maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Overweight and raises the price target from $200 to $208.

GOOG

GOOGL

JP Morgan Maintains Overweight on Alphabet, Raises Price Target to $208

Stifel analyst Benjamin Nolan maintains International Seaways (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) with a Buy and raises the price target from $68 to $72.

INSW

Stifel Maintains Buy on International Seaways, Raises Price Target to $72

Stifel analyst Benjamin Nolan maintains DHT Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>) with a Hold and raises the price target from $12 to $13.

Stifel Maintains Hold on DHT Holdings, Raises Price Target to $13

SIFY

Sify Technologies Receives Nasdaq Notice Of Non-Compliance With Minimum Bid Price Rule; ADSs Below $1.00 For 31 Consecutive Days

The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)
Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXR#NASDAQ">DXR</a>), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminates the need for hematocrit testing from third-party devices to perform the BVA test.

Contracts

Daxor Awarded $550K U.S. Defense Health Agency Contract For Added Capabilities To Its Point-Of-Care Blood Volume Analyzer

Management

Metalla Royalty & Streaming Appoints Jason Cho As President Effective Immediately

SolarMax Technology, Inc. (Nasdaq SMXT) ("SolarMax" or the "Company"), an integrated solar energy company, announced that it plans to offer engineering, procurement and construction services, known as EPC services, for large scale solar systems in the United States, which would include both solar power and EV charging stations. As the initial step in this business plan, SolarMax has signed a non-binding memorandum of understanding for its first major commercial solar installation project in the United States. This proposed project, to be located in Las Vegas, marks a potentially significant milestone in SolarMax' strategy to offer large scale EPC services in the U.S. EPC services encompass the comprehensive management of a solar project from the initial feasibility studies and design through procurement and construction.

Global

SMXT

SolarMax Technology Plans To Offer Engineering, Procurement And Construction Services In The United States; Signs MOU For First Major Commercial Solar Installation Project

Stifel analyst Benjamin Nolan maintains Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) with a Hold and raises the price target from $12 to $14.

CMRE

Stifel Maintains Hold on Costamare, Raises Price Target to $14

Keybanc analyst Thomas Blakey maintains Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) with a Overweight and raises the price target from $37 to $41.

APPN

Keybanc Maintains Overweight on Appian, Raises Price Target to $41

Studies Pre-Funded, No Additional Capital Needed; Expected Completion Early Q3 2024

MGRX

Mangoceuticals Initiates Efficacy Studies On Patented Respiratory Illness Prevention Technology In Collaboration With Vipragen Biosciences And IntraMont Technologies

PMEC

Primech Holdings FY24 Revenue $72.5M, Up 5.1% YoY, Contracted Revenues As Of Mar 31 Were $144.4M

LCNB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCNB#NASDAQ">LCNB</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.18 by 61.11 percent. This is a 35.56 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $19.30 million which beat the analyst consensus estimate of $17.20 million by 12.19 percent. This is a 8.27 percent increase over sales of $17.82 million the same period last year.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

MicroAlgo

News

Latest news for MicroAlgo (OTC:VENAF) Stock